Filtered By:
Specialty: Universities & Medical Training
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 257 results found since Jan 2013.
Relation of apixaban bleeding rates to dose in patients with chronic kidney disease
The objective of this study was to evaluate the safety and efficacy of apixaban 5 mg twice daily vs 2.5 mg twice daily for nonvalvular atrial fibrillation or venous thromboembolism in patients with chronic kidney disease stage 4 and 5, including those on hemodialysis. Data were collected retrospectively on patients with advanced chronic kidney disease and nonvalvular atrial fibrillation and/or venous thromboembolism who received apixaban while hospitalized at our institution between January 2013 and August 2018. The 5 mg twice daily group included 22 patients, and the 2.5 mg twice daily group included 73 patients. There wa...
Source: Baylor University Medical Center Proceedings - August 30, 2021 Category: Universities & Medical Training Authors: Sarah Yun Regan Sevinsky Tasleem Spracklin Alexandra Tatara Andrew Zoltan Fenves Source Type: research
Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?
Conclusions: In our study the incidence of SEC/LAT, particularly in AF with unknown duration, was not as low as we expected. The prevalence of SEC/LAT seemed to be dependent on factors not routinely evaluated in AF patients planned for cardioversion (indexed LA volume, LAA morphology and number of lobules, LAA emptying velocity, etc.). Our data suggested an individualized approach for DOAC duration in AF patients before an attempt for restoration of sinus rhythm is made, taking into consideration the LAA morphology and function.PMID:34072778 | DOI:10.3390/medicina57060554
Source: Medicina (Kaunas) - June 2, 2021 Category: Universities & Medical Training Authors: Stefan Naydenov Nikolay Runev Emil Manov Source Type: research
